Linnea’s Vincamine obtains a CEP certificate

July 5th 2024

 

 

 

The European Directorate for the Quality of Medicines & Healthcare (EDQM) has issued a CEP certificate for our Vincamine product, making Linnea the first company in the world to have a CEP-certified Vincamine extract.

CEP is a Certificate of Suitability to the monographs of the European Pharmacopoeia that centralizes the evaluation of the quality of pharmaceutical substances, and consequently certifies the compliance of the Active Pharmaceutical Ingredient (API) with the rules and specifications stated in the European Pharmacopoeia. Moreover, the CEP certification offers the advantage to speed up and simplify the regulatory lifecycle management in the countries where it is recognized.

Voacanga africana seeds representing Linnea’s CEP-certified Vincamine extract.
The European Directorate for the Quality of Medicines & Healthcare issued a CEP certificate for Linnea's Vincamine product. Linnea is the first company in the world to have a CEP-certified Vincamine extract.

To see the list of countries where the CEP certification is recognized, visit the EDQM website.

To learn more about Linnea’s portfolio, contact us at

e-mail: [email protected]

phone +41 91 850 50 55


Share
Print

Education, Community and Thought Leadership


Linnea goes beyond manufacturing to support our customers, connect with the community, and educate worldwide about the potential therapeutic benefits of our ingredients

Get the latest
Linnea® news